Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARKS: PK and Safety of Sublingual Epinephrine (DESF) in Pediatric Patients with Allergic Reactions
NCT07703982Phase 1Completed
- Sponsor
- Aquestive Therapeutics
- Start
- Dec 2024
- Primary completion
- Mar 2025
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of DESF in allergic reaction, sponsored by Aquestive Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Curve from Time 0 to 10 Minutes and 3 more. Started Dec 2024; status: completed.
02
Drugs
DESF
03
Conditions
allergic reaction
Beyond the preview
Go deeper on NCT07703982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07703982.